New Publication Reviewing Percutaneous PNS in the Management of Chronic  Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets

 // News

June 11  

Cleveland, Ohio – June 11, 2024 – SPR® Therapeutics, a leader in the use of peripheral nerve  stimulation (PNS) to address different types of pain throughout the body, announced the  publication of a review of prospective studies evaluating the impact on chronic pain following  percutaneous PNS treatment. Published in Pain Management, the review identified studies  evaluating PNS treatment for three primary treatment applications: low back pain, shoulder pain,  and neuropathic pain. Studies included in the review all utilized treatment with short-term  percutaneous PNS for up to 60 days with leads placed to target participants’ specific pain.  

Key takeaways from the publication included:  

  • This review of prospective studies evaluating percutaneous PNS treatments for chronic  pain summarizes the evidence, including multiple randomized controlled trials, across  etiologies and nerve targets demonstrating the ability of this neurostimulation treatment  to provide sustained relief of pain and the interference of pain with function without the  need for implantation of a permanent PNS system.  
  • Across studies, 73 percent of participants (n=137/187) had at least 50 percent  reductions in pain intensity and/or pain interference at the end of treatment. 
  • For included studies with long term follow-up, a majority of patients (57 percent,  n=62/108) reported sustained improvements in pain and/or pain interference through 12- 14 months. 
  • Cumulatively, there were no serious adverse events or unanticipated device-related  complications reported across all studies that met the inclusion criteria for this review. 
  • The collected evidence supports the use of percutaneous PNS as a nonopioid, non neurodestructive treatment option for chronic pain patients. 

Read the full publication here: A Review of Prospective Studies Regarding Percutaneous  Peripheral Nerve Stimulation Treatment in the Management of Chronic Pain 

“The studies and data evaluating the impact of PNS on chronic pain were clear in demonstrating  the potential of PNS to provide durable, sustained relief for patients,” said Dr. Scott Pritzlaff,  M.D., author, Associate Professor, Division of Pain Medicine University of California-Davis  School of Medicine and SPR consultant. “This short-term, nonopioid treatment approach with a  strong safety profile and positive results offers physicians and patients an option to consider  before requiring a permanent implant to address chronic pain.” 

“Chronic pain remains a significant challenge for millions of Americans, impacting their quality of  life, productivity, and ability to function and the utilization of PNS treatment offers a pathway to better outcomes for many,” said Maria Bennett, President, CEO and Founder of SPR  Therapeutics. “This publication builds upon our extensive clinical library and real-world evidence which has demonstrated exemplary consistency in reducing pain. We continue to see long lasting pain relief following just a 60-day treatment period.”  

About the SPRINT PNS System  

The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of  pain. Our breakthrough, 60-day treatment is a First-Line PNSoption uniquely proposed  to recondition the central nervous system to provide significant and sustained relief from chronic  pain — without a permanent implant, nerve destruction or the risk of addiction. The system has  been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and  chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by  leading pain management centers. Market research indicates that this breakthrough  neuromodulation treatment is a patient-preferred alternative to more invasive options. 

The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic,  intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not  intended to be placed in the region innervated by the cranial and facial nerves. 

Physicians should use their best judgment when deciding when to use the SPRINT PNS  System. For more information see the SPRINT PNS System IFU. Most common adverse events  are skin irritation and erythema. Results may vary. Rx only. 

For additional information regarding safety and efficacy, visit: SPR Safety Information.  

About SPR Therapeutics, Inc. 

SPR Therapeutics is a privately held medical device company, providing patients with a non opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical  unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.  Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment  of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and  knee) and back pain markets and built an incredibly strong foundation for commercial growth.  Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN,  SPR’s Senior Management team includes experienced industry veterans with nearly 200 years  of collective pain market and MedTech expertise, all driven by our purpose – to improve the  quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free  solution to manage their acute and chronic pain.  More information can be found at

SPR Contacts:
Michelle McDonald
Vice President – Marketing
[email protected]
Dave Folkens

Public Relations
[email protected]

Success message!
Warning message!
Error message!